Independence Contract Drilling Inc. Backs AtaCor Medical's Innovative Cardiac Rhythm Management Study

### Innovations in Cardiac Rhythm Management: AtaCor Medical's Pivotal Study Advances

AtaCor Medical, Inc. is making significant strides in the field of cardiac rhythm management with its latest announcement regarding a financing round of up to $75 million. This funding is dedicated to supporting a pivotal study for the Atala™ lead and extravascular implantable cardioverter-defibrillator (EV-ICD) system, which aims to treat life-threatening ventricular tachyarrhythmias. The Atala™ lead boasts a groundbreaking design that enables reliable sensing, antitachycardia pacing (ATP), and shock therapies without the need for traditional intravascular leads, which can carry long-term health risks. By using a small left parasternal incision for implantation, the lead is positioned through the rib space, with electrodes placed against the pericardium, representing a pivotal shift in how these life-saving devices can be deployed.

The innovative approach of the Atala™ lead allows for the placement of a pulse generator in either a lateral or pectoral subcutaneous pocket, streamlining the procedure and enhancing its overall efficacy. Rick Sanghera, the CEO of AtaCor, underscores the importance of developing systems that deliver comprehensive tachyarrhythmia therapies while simplifying the implantation process. This innovation not only caters to the immediate needs of patients but also addresses the long-term implications of traditional methods that often involve more invasive procedures and associated complications. Such advancements have the potential to redefine patient experiences and outcomes in cardiac care.

Moreover, AtaCor's commitment to innovation is further illustrated by the completion of patient enrollment in its ASCEND EV Pilot Study, with initial results set to be presented at the upcoming Asia Pacific Heart Rhythm Society (APHRS) meeting. This progress showcases AtaCor’s dedication to providing cutting-edge solutions that prioritize heart health while catering to critical management needs in cardiac rhythm disorders. The capital infusion from the recent financing round is expected to accelerate the development and availability of the Atala™ lead, bringing this vital technology closer to patients who need it most.

In addition to the financial backing, the enthusiasm expressed by Maria Berkman, Chair of the AtaCor Board of Directors, highlights the company's strategic focus on advancing pivotal clinical trials. The ongoing studies reflect a broader commitment within the medical device industry to enhance patient care through innovative technologies. As AtaCor moves forward, its efforts could set new standards in cardiac rhythm management, potentially improving outcomes for patients facing severe cardiovascular challenges.